Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Profit After Tax: 2014-2024

Historic Profit After Tax for Spyre Therapeutics (SYRE) over the last 11 years, with Dec 2024 value amounting to -$208.0 million.

  • Spyre Therapeutics' Profit After Tax rose 83.80% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.0 million, marking a year-over-year increase of 30.68%. This contributed to the annual value of -$208.0 million for FY2024, which is 38.60% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Profit After Tax of -$208.0 million as of FY2024, which was up 38.60% from -$338.8 million recorded in FY2023.
  • Spyre Therapeutics' 5-year Profit After Tax high stood at -$65.8 million for FY2021, and its period low was -$338.8 million during FY2023.
  • For the 3-year period, Spyre Therapeutics' Profit After Tax averaged around -$210.2 million, with its median value being -$208.0 million (2024).
  • Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 304.21% in 2023, then skyrocketed by 38.60% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Profit After Tax (Yearly) stood at -$80.9 million in 2020, then grew by 18.66% to -$65.8 million in 2021, then declined by 27.38% to -$83.8 million in 2022, then slumped by 304.21% to -$338.8 million in 2023, then skyrocketed by 38.60% to -$208.0 million in 2024.